Trupanion is the New GameStop: Partners With Chewy, 4 million Shares Short on Thin Volume

 I created this blog as there is too much censorship on the Wallstreetbets Reddit forum now and it's bought and paid for by the institutions. They say to never trust an anonymous blogger on the internet. And I am an anonymous blogger. I have my reasons for remaining anonymous, and those reasons don't matter. Can you really trust articles on Bloomberg or Wall Street Journal any more than an anonymous opinion? All I ask is to debate the content of my message. Not who I am or my motivations. If you agree with what I say and think that it's in-depth, quality and truthful work, then make sure to share this on every retail channel available to you. Reddit, Discord, Stocktwits, Twitter, Telegram, Whatsapp, Tiktok and wherever else. I have just added a follow option at the top left for those who want to be notified when more blogs come out. 

Today's alert is on Trupanion, Inc. (TRUP) which announced it's teaming up with Chewy, Inc. (CHWY) to offer pet insurance to Chewy's base. If you recall, CHWY founder Ryan Cohen was the one who joined GameStop (GME) to initiate a turnaround plan, causing the famous short squeeze. TRUP is ripe to become the next GME. It's up around 27% today to $142, but the important thing is that it's up on only 570,000 of volume.

This is the share statistics of TRUP from Yahoo Finance. There are 4 million shares short on a float of 31 million, a decent short interest of 13%. But the bigger issue is that TRUP is very thinly traded. It has an average daily volume of about 350,000 and like I said it's up 27% on only 570,000 shares traded so far today. If shorts are forced to cover, this can be an easy squeeze to $200 or more. 





Comments

Post a Comment

Popular posts from this blog

The Two Best Biotech Short Squeeze Candidates And The Next Carvana

Image
With the market having recovered most of its recent drop to be near all-time highs once again, shorts have been destroyed and are in a desperate spot. Heavily shorted stocks like B. Riley Financial, Inc. (RILY), Globe Life Inc. (GL) and Carvana Co. (CVNA) have been on absolute tears. We have written about CVNA before , as well as the impact of CVNA's move on Root , Inc. (ROOT). When a stock is squeezing like CVNA, a related stock like ROOT will follow suit. Shorts are often shorting multiple related stocks. Most don't even hide it with Kerrisdale openly bragging about its poor track record. GL was another one that was attacked by shorts which we talked about as a gamma squeeze candidate that has worked out very well over the past three weeks.  In this market of short squeezes, we have identified two excellent biotech short squeeze candidates, ImmunityBio, Inc. (IBRX) and Soleno Therapeutics, Inc. (SLNO). IBRX is starting up the production and sale of its cancer drug ANKT...
Read more

The Next NVDA-Backed Runner and New Asian IPO Squeeze Play

Image
We have seen stocks like Super Micro Computer, Inc. (SMCI) and SoundHound AI, Inc. (SOUN) have incredible squeeze runs thanks to their connection to NVIDIA Corporation (NVDA). We think the next one will be Spire Global, Inc. (SPIR), which popped a week ago after it announced a collaboration with NVDA to enhance AI-driven weather prediction. A few day later it dropped on the announcement of a financing at $14, with the potential to raise $61 million if warrants at $14.50 are exercised. We think there is a good chance that NVDA got in on this financing, as it tends to invest in the companies it does these deals with when spreading AI across different sectors. One such recent example was with Recursion Pharmaceuticals, Inc. (RXRX) for AI in drug development.  It looks like SPIR didn't really need this financing as it has enough cash and looks like it will be cash flow and net income positive in 2024. This financing was of a strategic nature, not something led by broker...
Read more

Forget about CVNA, PLCE is the Next Major Short Squeeze Play

Image
 Back in June, we called out Kerrisdale Capital and its short on Carvana Co. (CVNA) in our piece " Carvana: The Gamma Squeeze is Real, Time to Bankrupt Kerrisdale ". Kerrisdale has a history of calling one bad short after another, creating a squeeze on all of its positions as the firm and its associates face liquidity crises. Kerrisdale is once again on a cold streak as its short on Altimmune, Inc. (ALT) simultaneously blew up just as CVNA headed from $70 to $80 this week.  However, we think CVNA is done for now. Recall that in June after the initial spike to nearly $30, the stock pulled back to $20 before hitting $40 in the next month. People who are riding weekly call options aren't likely to cash in. CVNA looks headed to the mid to low $60's to close the gap that currently exists in the $62 to $66 area before resuming any further rise. Kerrisdale created an artificial short squeeze with its report, but now that both ALT and CVNA have come down from their weekly hig...
Read more